AngioDynamics Affirms FY2026 Adj EPS Guidance of $(0.33)-$(0.23) vs $(0.33) Est; Raises FY2026 Sales Guidance from $308M-$313M to $312M-$314M vs $310.204M Est
Benzinga Newsdesk 10 months ago
NewsGuidance
Fiscal Year 2026 Financial GuidanceFor fiscal year 2026 the company now expects:Guidance Metric Guidance Action Current Guidance(as of January 6, 2026) Previous Guidance(as of October 2, 2025)Net
Fiscal Year 2026 Financial Guidance
For fiscal year 2026 the company now expects:
| Guidance Metric | Guidance Action | Current Guidance (as of January 6, 2026) | Previous Guidance (as of October 2, 2025) | |||
| Net Sales | Increased | $312 - $314 million | $308 - $313 million | |||
| Med Tech Net Sales Growth | Unchanged | 14% - 16% | 14% - 16% | |||
| Med Device Net Sales Growth | Increased | 0% - 1% | Flat | |||
| Gross Margin | Unchanged | 53.5% - 55.5% | 53.5% - 55.5% | |||
| Adjusted EBITDA | Increased | $8.0 - $10.0 M | $6.0 - $10.0 million | |||
| Adjusted EPS | Unchanged | ($0.33) – ($0.23) | ($0.33) – ($0.23) | |||
| Free Cash Flow | Unchanged | Positive for full year FY 2026 | Positive for full year FY 2026 |
Tariff Related Guidance Assumptions
For the full fiscal year 2026, the company continues to expect a $4.0 - $6.0 million impact from tariffs, which are included in the above provided guidance.